カテゴリ： GlobalData, アメリカ, 企業調査

Viking Therapeutics Inc (VKTX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Viking Therapeutics Inc (VKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8291
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：70
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Viking Therapeutics Inc (Viking Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company’s lead clinical program product candidate include VK5211, an orally available, non-steroidal selective androgen receptor modulator developed for the treatment of lean body mass loss in patients who have undergone hip fracture surgery. Its other pipeline product candidates include VK0214 for the treatment of orphan indication, a rare X-linked inherited neurological disorder; VK2809 developed for orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease; and VK0612, an inhibitor of fructose -1,6-biphosphatase for type 2 diabetes. Viking Therapeutics is headquartered in San Diego, California, the US.

Viking Therapeutics Inc (VKTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Viking Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Viking Therapeutics Raises USD2.5 Million in Venture Financing 11
Partnerships 12
Kennedy Krieger Institute Enters into Research Agreement with Viking Therapeutics 12
Viking Therapeutics Enters into Research Agreement with Academic Medical Center 13
Licensing Agreements 14
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 14
Equity Offering 16
Viking Therapeutics Prices Public Offering of Shares for USD175.7 Million 16
Viking Therapeutics Raises USD77.6 Million in Public Offering of Shares 18
Viking Therapeutics Raises USD63.3 Million in Public offering of Shares 20
Viking Therapeutics Plans to Raise up to USD9.6 Million in Public Offering of Shares 22
Viking Therapeutics Raises USD14.8 Million in Public Offering of Shares 23
Viking Therapeutics to Raise USD15 Million in Public Offering of Shares 24
Viking Therapeutics Raises USD1.3 Million in Private Placement of Shares 25
Viking Therapeutics to Raise USD4.3 Million in Private Placement of Shares and Warrants 26
Viking Therapeutics Raises USD1.6 Million in Public Offering of Shares 27
Viking Therapeutics Raises USD1.8 Million in Private Placement of Shares 28
Viking Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 29
Viking Therapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD10.8 Million 30
Viking Therapeutics Completes Exercise of Underwriter’s Over Allotment Option for IPO of Shares for USD27.6 Million 32
Debt Offering 34
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 34
Viking Therapeutics Inc – Key Competitors 35
Viking Therapeutics Inc – Key Employees 36
Viking Therapeutics Inc – Locations And Subsidiaries 37
Head Office 37
Recent Developments 38
Financial Announcements 38
Aug 09, 2018: Viking Therapeutics reports second quarter 2018 financial results and provides corporate update 38
May 09, 2018: Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 40
Mar 07, 2018: Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update 42
Nov 08, 2017: Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 44
Aug 09, 2017: Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 46
May 10, 2017: Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 48
Mar 21, 2017: Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 50
Corporate Communications 52
Jul 06, 2017: Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors 52
Product News 53
10/24/2017: Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis at the Annual Meeting of the American Association for the Study of Liver Diseases 53
10/23/2017: Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 87th Annual Meeting of the American Thyroid Association 55
10/04/2017: Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) 57
06/06/2017: Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) 58
Clinical Trials 60
Jun 05, 2018: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease 60
Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture 61
Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings 63
Sep 11, 2017: Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) 65
Sep 07, 2017: Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia at the 13th International Congress of Inborn Errors of Metabolism 66
Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture 68
Feb 09, 2017: Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Viking Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Viking Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Viking Therapeutics Raises USD2.5 Million in Venture Financing 11
Kennedy Krieger Institute Enters into Research Agreement with Viking Therapeutics 12
Viking Therapeutics Enters into Research Agreement with Academic Medical Center 13
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 14
Viking Therapeutics Prices Public Offering of Shares for USD175.7 Million 16
Viking Therapeutics Raises USD77.6 Million in Public Offering of Shares 18
Viking Therapeutics Raises USD63.3 Million in Public offering of Shares 20
Viking Therapeutics Plans to Raise up to USD9.6 Million in Public Offering of Shares 22
Viking Therapeutics Raises USD14.8 Million in Public Offering of Shares 23
Viking Therapeutics to Raise USD15 Million in Public Offering of Shares 24
Viking Therapeutics Raises USD1.3 Million in Private Placement of Shares 25
Viking Therapeutics to Raise USD4.3 Million in Private Placement of Shares and Warrants 26
Viking Therapeutics Raises USD1.6 Million in Public Offering of Shares 27
Viking Therapeutics Raises USD1.8 Million in Private Placement of Shares 28
Viking Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 29
Viking Therapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD10.8 Million 30
Viking Therapeutics Completes Exercise of Underwriter's Over Allotment Option for IPO of Shares for USD27.6 Million 32
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 34
Viking Therapeutics Inc, Key Competitors 35
Viking Therapeutics Inc, Key Employees 36

List of Figures
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Viking Therapeutics Inc (VKTX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Bank of Shanghai Co., Ltd.：企業の戦略・SWOT・財務情報
    Bank of Shanghai Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Shanghai Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Smiths Group Plc (SMIN)：企業の財務・戦略的SWOT分析
    Smiths Group Plc (SMIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Rockwool International AS：戦略・SWOT・企業財務分析
    Rockwool International AS - Strategy, SWOT and Corporate Finance Report Summary Rockwool International AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • The GPT Group：企業のM&A・事業提携・投資動向
    The GPT Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The GPT Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Wave 80 Biosciences Inc：企業の製品パイプライン分析2018
    Summary Wave 80 Biosciences Inc (Wave 80) is a medical device company that develops molecular diagnostic instruments and consumables. The company develops molecular diagnostics instruments for chlamydia, respiratory illness, cancers, autoimmune diseases, hepatitis B, hepatitis C, HIV/AIDS and other …
  • Somany Ceramics Limited (SOMANYCERA)：企業の財務・戦略的SWOT分析
    Somany Ceramics Limited (SOMANYCERA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Iowa Health System：企業の戦略的SWOT分析
    Iowa Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • juwi AG：電力：M&Aディール及び事業提携情報
    Summary juwi AG (juwi) a subsidiary of MVV Energie AG, is a renewable energy company that offers project development and engineering procurement and construction services; and products and solutions for the energy turnaround. It offers whole-scale project development services for the planning and co …
  • Proximus plc：企業の戦略・SWOT・財務分析
    Proximus plc - Strategy, SWOT and Corporate Finance Report Summary Proximus plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • BASF Corp：企業のM&A・事業提携・投資動向
    BASF Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BASF Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • DIRECT Pojistovna, a.s.：企業の戦略・SWOT・財務分析
    DIRECT Pojistovna, a.s. - Strategy, SWOT and Corporate Finance Report Summary DIRECT Pojistovna, a.s. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • NTT DOCOMO, Inc.：企業のM&A・事業提携・投資動向
    NTT DOCOMO, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NTT DOCOMO, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • NH Hotel Group, S. A. (NHH)：企業の財務・戦略的SWOT分析
    NH Hotel Group, S. A. (NHH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Amazon.com Inc (AMZN)：企業の財務・戦略的SWOT分析
    Amazon.com Inc (AMZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Tessi S.A. (TES)：企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Tenaga Nasional Bhd (TENAGA)：電力：M&Aディール及び事業提携情報
    Summary Tenaga Nasional Bhd (TNB) is an electricity utility that generates, transmits, distributes and supplies power. It develops, operates and maintains a portfolio of power generating units. The company produces electricity from crude oil, natural gas, hydro, coal and gas sources. TNB also suppli …
  • Federal Home Loan Mortgage Corporation：企業の戦略・SWOT・財務情報
    Federal Home Loan Mortgage Corporation - Strategy, SWOT and Corporate Finance Report Summary Federal Home Loan Mortgage Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Thermo Fisher Scientific Inc (TMO)：企業の財務・戦略的SWOT分析
    Thermo Fisher Scientific Inc (TMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Theravectys SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Theravectys SA (TheraVectys) is a clinical development biotech company that develops new generation therapeutic vaccines and immunotherapies. The company develops viral vectors vaccines to support body and prepare against future infections by pre-exposing immune system to partial, dead, inac …
  • Enel SpA：企業の戦略・SWOT・財務情報
    Enel SpA - Strategy, SWOT and Corporate Finance Report Summary Enel SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆